Recombinant monoclonal antibody to folate receptor 1. Farletuzumab (MORAb-003) is a monoclonal antibody which is being investigated for the treatment of ovarian cancer, It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.
Chemokines are a group of small (approximately 8 to 14 kD), mostly basic, structurally related molecules that regulate cell trafficking of various types of leukocytes through interactions with a subset of 7-transmembrane, G protein-coupled receptors. Chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis. Learn more: cxcl11 antibody
With years of research and development, Creative Biolabs has extensive experience in phage display platform by employing various types of phage in various project objectives. In general, filamentous bacteriophages (e.g. M13) are the most popular vehicle choice for phage display and extensively used in many types of research. Meanwhile, Creative Biolabs is also an expert to provide phage display related services via either T4 or T7 phage systems, which can provide different promising alternatives by their special merits.
Advanced discoveries in the field of immunology have partially unraveled the mysteries of the immune system. Among the unsung heroes protecting an organism from a variety of infections, γδ T cells have turned out to be a unique arm of the immune response. Their roles in anti-microbial defenses, epitomized by γδ T cell engagement in viral host defenses, are just beginning to be fully understood. Here, Creative Biolabs discusses the multi-Functions of γδ T Cells in Viral Infections.
Creative Biolabs has organized a staff of outstanding scientists who have engaged in γδ T cell research and γδ T cell based immunotherapy development for many years. We are committed to providing a full range of CAR engineered γδ T cell development services, including design and generation of CAR, CAR lentivirus production, γδ T cell preparation, transduction of activated γδ T cells with CAR-encoding lentivirus, and validation of CAR γδ T cell. Our one-stop high-quality services will accelerate the development of CAR-γδ T cells for tumor treatment.
γδ TCR variants Currently, γδ T cells have been considered as unique innate-like T cells with TCRs that can easily recognition of highly conserved antigens. Meanwhile, evidence has suggested that analyzing the γδ TCR repertoire is important to obtain meaningful data for the immune system features, the causes, and the progression of the disease. At present, the main obstacle to the problem of the γδ TCR repertoire services is that traditional methods are not sufficient to characterize the TCR repertoire in-depth.
In a recent article published in Nature, researchers identified pathways regulating γδ T-cell killing and BTN3A cell expression by integrating genome-wide CRISPR screening and tumor organoid culture, deepening the understanding of γδ T-cell stress surveillance and suggesting a new pathway to enhance the γδ T cells-based anti-cancer function.
Building upon deeply understanding of the signaling pathways and implications of immune checkpoint molecules, Creative Biolabs has developed a full-scale platform to develop immune checkpoint-associated antibodies, proteins, peptides, assays, small molecular drugs, etc. to meet different demands from our global customers.
Immune checkpoints are regulators to enhance or moderate immune responses. Immune checkpoint mechanisms are often activated to suppress the nascent anti-tumor immune response, which leads to the development of several immune checkpoint inhibitors, such as antibodies, peptides, and small molecular drugs for cancer therapy. Combined with broad technological expertise and the latest instrumentation, Creative Biolabs is dedicated to offering a wide range of immune checkpoint development services, including antibodies, proteins, peptides, assays, small molecular drugs, and more. Our experienced team can also save you time by providing customer service to meet your specifications.
Advances in Small Molecule Drugs Targeting PD-1/PD-L1 PD-1/L1 antibodies can be said to be the current hot direction in the development of targeted cancer drugs. However, monoclonal antibodies have many inherent drawbacks, including poor oral bioavailability, prolonged tissue retention time and half-life, poor membrane permeability, transportation and storage, etc. In addition, the high cost of antibody drugs is also a non-negligible problem. Therefore, more and more researchers are exploring small molecule drugs as PD-1/L1 inhibitors to circumvent the disadvantages of therapeutic antibodies.